Dosing Guidlines for Adults
Drug Detail for Adult Drugs
Vinblastine
Miscellaneous Agents
Antineoplastic Agents
- General Toxicity Notes
- Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
- Excreted Unchanged %
- None
- Half-Life (NormalESRD) hours
- 1.0-1.5/No data
- Plasma Protein Binding %
- 75
- Volume of Distribution L/kg
- 13-40
- Dose for Normal Renal Function
- 3.7 mg/m2
- Second Dose
-
- Adjustment for Renal Failure Method
- D
- Adjustment for Renal Failure GFR, mL/min >50 [Recommended Level]
- 100% [B]
- Adjustment for Renal Failure GFR, mL/min 10-50 [Recommended Level]
- 100% [B]
- Adjustment for Renal Failure GFR, mL/min <10 [Recommended Level]
- 100% [B]
- Supplement for Dialysis [Recommendation Level]: IHD
- IHD: None, [D]
- Supplement for Dialysis [Recommendation Level]: PD
- PD: None, [D]
- Supplement for Dialysis [Recommendation Level]: CRRT
- CRRT: Dose for GFR 10-50, [D]
- References
- Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res. 1977; 37: 2597-602. [PMID: 889590] / Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv. 1993; 17: 269-81. [PMID: 8137344]
- Toxicity Notes
- Vinca alkaloids may increase antidiuretic hormone secretion. Vd increases with time due to avid tissue binding.